Co-founder of Ousia Pharma. Postdoctoral fellow working on development of novel anti-obesity medicines. Chemistry.
Joined January 2019
- Tweets 52
- Following 486
- Followers 239
- Likes 1,150
3 Photos and videos
Pinned Tweet
15 May 2024
Excited and proud to see the main work from my PhD and postdoc on the development of "GLP-1 directed NMDA receptor antagonism for obesity treatment" out in @Nature today!
nature.com/articles/s41586-0…
1/7 🧵
8
30
169
26,065
📚In our Review, we synthesize the rapidly expanding knowledge across the field from the clinical breakthroughs that have reshaped obesity treatment, to the molecular mechanisms behind the next generation of obesity therapies now moving through the pipeline.
The evolving landscape of obesity pharmacotherapy
nature.com/articles/s41573-0…
rdcu.be/fiw7g
This new Review covers the evolution of obesity therapy from GLP1s to multi-receptor agonists, oral formulations, weight-loss quality approaches and tissue-specific drug targeting
2
64
Jonas Odgaard Petersen retweeted
The evolving landscape of obesity pharmacotherapy
nature.com/articles/s41573-0…
rdcu.be/fiw7g
This new Review covers the evolution of obesity therapy from GLP1s to multi-receptor agonists, oral formulations, weight-loss quality approaches and tissue-specific drug targeting
3
67
191
12,548
Jonas Odgaard Petersen retweeted
7 Aug 2025
1/8
🧠 New review from the lab in @CellCellPress: Brain Control of Energy Homeostasis
We explore how central nervous system circuits regulate energy balance, and how this informs the development of next-generation obesity pharmacotherapies.
🔗 cell.com/cell/fulltext/S0092…
8
46
153
42,228
4 Mar 2025
Thrilled to have contributed to this snapshot article on "Brain-Targeting Anti-Obesity Medications" appearing today in @Cell_Metabolism on #WorldObesityDay.
4 Mar 2025
On #WorldObesityDay, we have contributed a SnapShot to a special Issue on Obesity in @Cell_Metabolism covering brain actions of the current and emerging weight loss drugs. @OdgaardJonas @JohansenVBI
@UCPH_health
Free access link: authors.elsevier.com/a/1kiaA…
5
196
Jonas Odgaard Petersen retweeted
16 Sep 2024
1/4 New paper out in @MolMetab in which we show that calorie restriction before starting treatment with semaglutide or tirzepatide pushes maximum achievable weight loss by ~8% sciencedirect.com/science/ar…
1
10
37
6,595
Jonas Odgaard Petersen retweeted
3 Jul 2024
A few months back, we published a study in @ScienceAdvances demonstrating the potential of targeting postsynaptic glutamate receptor scaffolding proteins, such as PSD-95, for sustained weight loss. Headed by @nicolefadahunsi, @OdgaardJonas and @Met_Sop science.org/doi/10.1126/scia…
1
3
38
3,458
Jonas Odgaard Petersen retweeted
21 Jun 2024
Big day for the lab as our latest paper is out in Nature Chemical Biology @nchembio on identifying the oxybipins as new OSBP inhibitors, as well as their mechanism of action and therapeutic applications! nature.com/articles/s41589-0… 1/n
6
28
128
13,940
Jonas Odgaard Petersen retweeted
4 Jun 2024
Research Highlight in @NatRevDrugDisc covering our recent paper on targeted NMDA receptor antagonism for obesity treatment nature.com/articles/d41573-0…
6
32
2,325
Jonas Odgaard Petersen retweeted
17 May 2024
Insightful News and Views´ from @Tcook30 and @DarleenSandoval on our recent paper.
1
31
141
17,557
15 May 2024
4/7 To safely harvest the appetite-modulating effects of NMDAR antagonism, we engineered a first-in-class dual-acting compound that chemically combines GLP-1R agonism and NMDAR antagonism in a single Trojan horse like molecule.
1
7
599
15 May 2024
6/7 Check out the informative thread by @ClemmensenC. It has been absolutely amazing working on this piece together, and I am excited to continue working on the next-generation of compounds in @OusiaPharma together with @BueKlein with support from @BioCPH and @Innofond .
1
5
415
15 May 2024
7/7 Kudos to all the people involved in this massive collaborative effort from the labs of @ClemmensenC @stromgaardlab @Froelund_lab @tunepers @thewilliamslab @KAKohlmier @atul_deshmukh1 @Thue_Schwartz and @MortenBThomsen from @Metabolcenter at @koebenhavns_uni @UCPH_health
1
1
6
569
15 May 2024
2/7 Genome-wide association studies inform that the CNS should be regarded as a primary target for obesity treatment, and highlights glutamatergic signaling and NMDA receptor-related neuroplasticity in body weight homeostasis.
nature.com/articles/nature14…
1
4
576
15 May 2024
3/7 Inspired by these findings, we embarked on the idea of therapeutically leveraging NMDAR pharmacology for treatment of obesity. We found that NMDAR antagonism potently lowers body weight in obese mice, but that the therapeutic utility is hampered by intolerable adverse effects
2
6
442
15 May 2024
Excited and proud to see the main work from my PhD and postdoc on the development of "GLP-1 directed NMDA receptor antagonism for obesity treatment" out in @Nature today!
nature.com/articles/s41586-0…
1/7 🧵
8
30
169
26,065
Jonas Odgaard Petersen retweeted
9 Feb 2024
Exciting news! My main paper for my PhD in the @ClemmensenC lab with @pranea is now published in @naturecomms! 🎉 It delves into how the body is naturally defended against excessive weight gain. A🧵👇#obesityresearch 1/11 nature.com/articles/s41467-0…
10
33
133
29,137
25 Oct 2023
🏆 I am deeply honored to be one of the recipients of the UCPH: BII Life Science Innovation Award 2023 at the SUND Innovation Day 2023. It was truly exciting to showcase our innovative solutions that were born in the @ClemmensenC lab and later incorporated to @OusiaPharma.
We couldn't be more proud of Postdoc @OdgaardJonas and PhD Student @SassFrederike for being among the winners of the UCPH: @BioCPH Life Science Innovation Award at the @UCPH_health Innovation day! 🏆
CBMR is committed to translating its discoveries to accelerate the prediction, prevention, diagnosis and treatment of cardiometabolic disease. 🚀
Learn more about CBMR's Innovation Strategy on our website 👇
cbmr.ku.dk/translation/
4
29
2,081
Jonas Odgaard Petersen retweeted
26 Jun 2023
Fascinating developments in weight loss drugs! Eli Lilly's triagonist phase 2 data: Nearly half of participants achieved >25% weight loss, with a quarter surpassing the impressive >30% mark. The bar continues to rise for incretin-based therapies.
nejm.org/doi/full/10.1056/NE…
1
12
65
5,426
Jonas Odgaard Petersen retweeted
8 Jun 2023
The first Danish peptide symposium takes place in Copenhagen on August 31
eventsignup.ku.dk/danishpept…
1
15
68
8,144